Birgül KIREL, Gonca KILIÇ YILDIRIM, İlhan HAZER, Hilmi Onur KABUKÇU, Murat YAĞCI, Zeynep ERTÜRK

Obez çocuklarda lipid metabolizması ile non-alkolik yağlı karaciğer hastalığı ilişkisi

Amaç: Obezite, insülin direnci ve hiperlipidemi non-alkolik yağlı karaciğer hastalığı risk etmenleri olarak gösterilmektedir. Bu çalışmada obezite tanılı hastalarda lipid ve lipoprotein metabolizması anormallikleri ile non-alkolik yağlı karaciğer hastalığı varlığı arasındaki ilişkili araştırılmıştır.Gereç ve Yöntemler: Bu çalışmada; 2013–2018 yılları arasında obezite tanısı alan, yaşları 2–18 yıl arasında değişen 357 çocuk ve ergen hastanın (199 kız, 158 erkek) klinik, laboratuvar ve görünteleme bulguları geriye dönük olarak incelendi. Ultrasonografi ile non-alkolik yağlı karaciğer hastalığı saptanan hastaların klinik ve laboratuvar özellikleri non-alkolik yağlı karaciğer hastalığı olmayan hastalar ile karşılaştırıldı. Tüm lipid ve lipoproteinler kendi içlerinde yaşa ve cinsiyete göre referans değerleri ile karşılaştırılarak; hipo-, normo- ve hiperlipidemik olarak kaydedildi.Bulgular: Tüm çalışma grubunda non-alkolik yağlı karaciğer hastalığı görülme sıklığı %44,5 idi ve erkeklerde sıklık daha yüksekti (p

The association of lipid metabolism and non-alcoholic fatty liver disease in children with obesity

Aim: Obesity, insulin resistance, and hyperlipidemia have been shownas risk factors for non-alcoholic fatty liver disease. In this study, the association between lipid and lipoprotein metabolism abnormalities andthe presence of non-alcoholic fatty liver disease was investigated in patients with obesity.Material and Methods: In this study, the clinical, laboratory and imagingfindings of 357 children and adolescent patients (199 girls and 158 boys)aged 2–18 years who were diagnosed as having obesity between 2013and 2018 were retrospectively analyzed. The clinical and laboratory features of the patients who were diagnosed as having non-alcoholic fattyliver disease using ultrasonography were compared with patients whodid not have non-alcoholic fatty liver disease. All lipid and lipoproteinlevels were defined as hypo-, normo- and hyperlipidemic in comparisonwith the reference values according to age and sex.Results: The frequency of non-alcoholic fatty liver disease was 44.5%in the entire study group and was higher in males (p

PDF

___

Shah J, Okubote T, Alkhouri N. Overview of Updated Practice Guidelines for Pediatric Nonalcoholic Fatty Liver Disease. Gastroenterol Hepatol (N Y) 2018; 14: 407–14.
Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2018; 67: 328–57.
Feldstein AE, Charatcharoenwitthaya P, Treeprasertsuk S, Benson JT, Enders FB, Angulo P. The natural history of non-alcoholic fatty liver disease in children: a follow-up study for up to 20 years. Gut 2009; 58: 1538–44.
Anderson EL, Howe LD, Jones HE, Higgins JP, Lawlor DA, Fraser A. The Prevalence of Non-Alcoholic Fatty Liver Disease in Children and Adolescents: A Systematic Review and Meta-Analysis. PLoS One 2015; 10: e0140908.
Gokce S, Atbinici Z, Aycan Z, Çınar HG, Zorlu P. The relationship between pediatric non-alchololic fatty liver disease and cardiovasculer risk factors and increased risk of atherosclerosşs in obese children. Pediatr Cardiol 2013; 34: 308–15.
Yıldız I, Erol OB, Toprak S, et al. Role of vitamin D in children with hepatosteatosis. J Pediat Gastr Nutr 2014; 59: 106–11.
Akcam M, Boyaci A, Pirgon O, Koroglu M, Dundar BN. Importance of the liver ultrasound scores in pubertal obese children with nonalcoholic fatty liver disease. Clin Imaging 2013; 37: 504–8.
Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents; National Heart, Lung, and Blood Institute. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics 2011; 128: S213–56.
Iqbal U, Perumpail BJ, John N, et al. Judicious Use of Lipid Lowering Agents in the Management of NAFLD. Diseases 2018; 6: 87.
Bamba V. Update on screening, etiology, and treatment of dyslipidemia in children. J Clin Endocrinol Metab 2014; 99: 3093–02.
Speliotes EK, Massaro JM, Hoffmann U, et al. Fatty liver is associated with dyslipidemia and dysglycemia independent of visceral fat: the Framingham Heart Study. Hepatology 2010; 51: 1979–87.
Welty FK. Hypobetalipoproteinemia and abetalipoproteinemia. Curr Opin Lipidol 2014; 25: 161–8.
Muñoz Torres M, Cano Romera A, Domínguez S, Cano Parra MD, Lobón JA, Escobar Jiménez F. Familial hypobetalipoproteinemia: description of a heterozygous form with important biochemical alterations. [Article in Span-ish]. Rev Clin Esp 1991; 188: 81–2.
Wishingrad M, Paaso B, Garcia G. Fatty liver due to heterozygous hypobetalipoproteinemia. Am J Gastroenterol 1994; 89: 1106–7.
Hagve TA, Myrseth LE, Schrumpf E, et al. Liver steatosis in hypobetalipoproteinemia. A case report. J Hepatol 1991; 13: 104–11.
Virani SS. Non-HDL cholesterol as a metric of good quality of care: opportunities and challenges. Tex Heart Inst J 2011; 38: 160–2.
Willian AN, Collin CJ. Disorders of lipoprotein metabolism and transport. In: Kliegman RM, St. Geme J, editors. Nelson Textbook of Pediatrics. 20th Edition volüme, 1st Edition. Philadelphia: John F. Kennedy Blvd; 2016.p.691– 705.
Kurtoğlu S, Hatipoğlu N, Mazıcıoğlu M, Kendirici M, Keskin M, Kondolot M. Insulin resistance in obese children and adolescents: HOMA-IR cut-off levels in the prepubertal and pubertal periods. J Clin Res Pediatr Endocrinol 2010; 2: 100–6.
Day CP, James OF. Steatohepatitis: a tale of two hits? Gastroenterology 1998; 114: 842–5.
Levenson AE, de Ferranti SD. Familial hypercholesterolemia. (Updated 2016 Jun 22). In: De Groot LJ, Chrousos G, Dungan K, editors. Endotext [Internet] South Dartmouth, MA: MDText.com, Inc; 2000.
Bozic MA, Subbarao G, Molleston JP. Pediatric nonalcoholic fatty liver disease. Nutr Clin Pract 2013; 28: 448–58.
Zheng R, Du Z, Wang M, Mao Y, Mao W. A longitudinal epidemiological study on the triglyceride and glucose index and the incident nonalcoholic fatty liver disease. Lipids Health Dis 2018; 17: 262.
Dowla S, Aslibekyan S, Goss A, Fontaine K, Ashraf AP. Dyslipidemia is associated with pediatric nonalcoholic fatty liver disease. J Clin Lipidol 2018; 12: 981–7.
Elmaoğulları S, Tepe D, Uçaktürk SA, Karaca Kara F, Demirel F. Prevalence of Dyslipidemia and Associated Factors in Obese Children and Adolescents. J Clin Res Pediatr Endocrinol 2015; 7: 228–34.
Hashemipour M, Soghrati M, Malek Ahmadi M, Soghrati M. Anthropometric indices associated with dyslipidemia in obese children and adolescents: a retrospective study in isfahan. ARYA Atheroscler 2011; 7: 31–9.
Evia-Viscarra ML, Rodea-Montero ER, Apolinar-Jiménez E, Quintana-Vargas S. Metabolic syndrome and its components among obese (BMI >=95th) Mexican adolescents. Endocr Connect 2013; 2: 208–15.
27. Steiner G. Hyperinsulinemia and VLDL kinetics. Adv Exp Med Biol 1993; 334: 287–94.
Castellano G, Garfia C, Gomez-Coronado D, et al. Diffuse fatty liver in familial heterozygous hypobetalipoproteinemia. J Clin Gastroenterol 1997; 25: 379–82.
Hsiao PJ, Lee MY, Wang YT, et al. MTTP-297H polymorphism reduced serum cholesterol but increased risk of non-alcoholic fatty liver disease-a cross-sectional study. BMC Med Genet 2015; 16: 93.
Dongiovanni P, Petta S, Maglio C, et al. Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease. Hepatology 2015; 61: 506–14.